CLL Coverage from Every Angle

Ian W. Flinn, MD, PhD, on Chronic Lymphocytic Leukemia: Early-Phase Research on Immunotherapy

Posted: Monday, August 19, 2019

Ian W. Flinn, MD, PhD, of the Sarah Cannon Research Institute, discusses the ZUMA-8 trial, a phase I/II multicenter study evaluating the safety and efficacy of KTE-X19 in adults with relapsed/refractory chronic lymphocytic leukemia.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.